283 related articles for article (PubMed ID: 17105822)
1. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
Rodríguez-Pinilla SM; Sarrió D; Honrado E; Moreno-Bueno G; Hardisson D; Calero F; Benítez J; Palacios J
J Clin Pathol; 2007 Sep; 60(9):1006-12. PubMed ID: 17105822
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
Rodríguez-Pinilla SM; Sarrió D; Honrado E; Hardisson D; Calero F; Benitez J; Palacios J
Clin Cancer Res; 2006 Mar; 12(5):1533-9. PubMed ID: 16533778
[TBL] [Abstract][Full Text] [Related]
3. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
4. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
5. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
[TBL] [Abstract][Full Text] [Related]
7. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
[TBL] [Abstract][Full Text] [Related]
8. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
[TBL] [Abstract][Full Text] [Related]
10. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
Rodríguez-Pinilla SM; Rodríguez-Gil Y; Moreno-Bueno G; Sarrió D; Martín-Guijarro Mdel C; Hernandez L; Palacios J
Am J Surg Pathol; 2007 Apr; 31(4):501-8. PubMed ID: 17414096
[TBL] [Abstract][Full Text] [Related]
11. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
[TBL] [Abstract][Full Text] [Related]
12. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
13. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
15. Centrally necrotizing carcinoma of the breast: clinicopathological analysis of 33 cases indicating its basal-like phenotype and poor prognosis.
Yu L; Yang W; Cai X; Shi D; Fan Y; Lu H
Histopathology; 2010 Aug; 57(2):193-201. PubMed ID: 20716161
[TBL] [Abstract][Full Text] [Related]
16. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
17. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
18. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.
Rodriguez-Pinilla SM; Sarrio D; Moreno-Bueno G; Rodriguez-Gil Y; Martinez MA; Hernandez L; Hardisson D; Reis-Filho JS; Palacios J
Mod Pathol; 2007 Apr; 20(4):474-81. PubMed ID: 17334350
[TBL] [Abstract][Full Text] [Related]
19. The molecular pathology of hereditary breast cancer.
Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
